These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

700 related items for PubMed ID: 30861172

  • 1. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
    Veloza L, Teixido C, Castrejon N, Climent F, Carrió A, Marginet M, Soldini D, González-Farré B, Ribera-Cortada I, Lopez-Guillermo A, González-Barca E, Sierra A, Herrera M, Gómez C, Garcia A, Balagué O, Campo E, Martinez A.
    Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y, Furuta T, Ohshima K, Komaki S, Miyoshi J, Morioka M, Abe H, Nozawa T, Fujii Y, Takahashi H, Kakita A.
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
    Ishikawa E, Kato S, Shimada K, Tanaka T, Suzuki Y, Satou A, Kohno K, Sakakibara A, Yamamura T, Nakamura M, Miyahara R, Goto H, Nakamura S, Hirooka Y.
    Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
    [Abstract] [Full Text] [Related]

  • 7. Epstein-Barr virus latency patterns in polymorphic lymphoproliferative disorders and lymphomas in immunodeficiency settings: Diagnostic implications.
    Volaric AK, Saleem A, Younes SF, Zhao S, Natkunam Y.
    Ann Diagn Pathol; 2024 Jun; 70():152286. PubMed ID: 38447253
    [Abstract] [Full Text] [Related]

  • 8. EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression.
    Xue T, Wang WG, Zhou XY, Li XQ.
    Pathology; 2018 Dec; 50(7):725-729. PubMed ID: 30389217
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
    Guo L, Bodo J, Durkin L, Hsi ED.
    Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma arising in patient with a history of EBV-positive mucocutaneous ulcer and EBV-positive nodal polymorphous B-lymphoproliferative disorder.
    Daroontum T, Kohno K, Inaguma Y, Okamoto A, Okamoto M, Kimura Y, Nagahama M, Sakakibara A, Satou A, Nakamura S.
    Pathol Int; 2019 Jan; 69(1):37-41. PubMed ID: 30450620
    [Abstract] [Full Text] [Related]

  • 12. Clinicopathological analysis of neoplastic PD-L1-positive EBV+ diffuse large B cell lymphoma, not otherwise specified, in a Japanese cohort.
    Takahara T, Satou A, Ishikawa E, Kohno K, Kato S, Suzuki Y, Takahashi E, Ohashi A, Asano N, Tsuzuki T, Nakamura S.
    Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
    [Abstract] [Full Text] [Related]

  • 13. Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance.
    Fisher KE, Ferguson LS, Coffey AM, Merritt BY, Curry JL, Marcogliese AN, Major AM, Kamdar KY, Lopez-Terrada DH, Curry CV.
    Haematologica; 2022 Aug 01; 107(8):1880-1890. PubMed ID: 35081690
    [Abstract] [Full Text] [Related]

  • 14. Age-related EBV-associated B-cell lymphoproliferative disorders and other EBV + lymphoproliferative diseases: New insights into immune escape and immunodeficiency through staining with anti-PD-L1 antibody clone SP142.
    Sakakibara A, Kohno K, Ishikawa E, Suzuki Y, Shimada S, Eladl AE, Elsayed AA, Daroontum T, Satou A, Takahara T, Ohashi A, Takahashi E, Kato S, Nakamura S, Asano N.
    Pathol Int; 2020 Aug 01; 70(8):481-492. PubMed ID: 32367595
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of genomic alterations in Epstein-Barr virus-positive and Epstein-Barr virus-negative diffuse large B-cell lymphoma.
    Liu F, Tian S, Liu Q, Deng Y, He Q, Shi Q, Chen G, Xu X, Yuan J, Nakamura S, Karube K, Wang Z.
    Cancer Med; 2024 Feb 01; 13(4):e6995. PubMed ID: 38457199
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer.
    Li LL, Yu AY, Zhu M, Ma LY, Cao MH, Liu WL, Qin XB, Gao C, Han ZX, Wang HM.
    Arch Virol; 2024 May 03; 169(5):114. PubMed ID: 38700535
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.